Edwards Lifesciences Comments on CMS National Coverage Analysis of Transcatheter Heart Valves

Edwards Lifesciences Corporation EW today issued the following statement regarding the initiation of a National Coverage Analysis of transcatheter aortic valve replacement by the Centers for Medicare & Medicaid Services: Edwards was aware for some time that CMS was considering initiating an NCA. The company believes a well-written National Coverage Determination that ensures adequate patient access to this important and rapidly evolving therapy would be a positive for patients and physicians. The NCD draft is just entering the public comment period, and we expect it to evolve as the societies, regulators and other stakeholders provide their input on the important details.